Category Archives: investing

Isracann Biosciences Announces OTC Trading Symbol Change to “ISCNF”, Effective November 15, 2019

Isracann Biosciences Announces OTC Trading Symbol Change to “ISCNF”, Effective November 15, 2019

Isracann Biosciences Inc.  (CSE: IPOT) (FRA: A2PT0E) (OTC: ISCNF) an Israel-based company focused on becoming a premier low cost, high quality cannabis producer for both Israeli and European export sales, is pleased to announce that the Financial Industry Regulatory Authority, Inc. has approved the Company’s request to change its OTC ticker symbol to ISCNF, effective as of the opening of market trading on November 15, 2019.

The previous trading symbol was ATLED and has been changed to more accurately represent our corporate brand and primary operations in the cannabis sector. The Company is also pleased to announce that it has secured DTC eligibility by The Depository Trust Company (“DTC”) for electronic settlement and transfer of its common shares in the United States.

“Trading under the new OTC ticker symbol ISCNF and achieving DTC eligibility is a major step forward in making it materially easier for US-based investors who are intrigued by the idea of buying shares in an Israeli cannabis venture operated by sector experienced entrepreneurs and capital markets professionals. Our strategic aim is straightforward and leverages the national brand excellence of the Israeli agricultural industry combined with planned industrial scale production of low cost premium quality cannabis targeting export into the massive European marketplace. It’s a uniquely scalable venture that combines numerous positive attributes including a team that knows how to execute,” stated Darryl Jones, Company CEO. “This is an important step in propelling our story to wider audiences and to materially grow our investor base.”

No action is required to be taken by current shareholders with relation to the trading symbol change, and no changes have been made to the Company’s share capital, management, or control. Isracann’s shares will continue to trade on the Canadian Securities Exchange (CSE) under the symbol CSE: IPOT, as well as the Frankfurt Stock Exchange under the symbol FRA: A2PT0E.

Updates relating to the additional corporate changes mentioned above will be announced as initiatives continue to progress.

ON BEHALF OF THE BOARD OF DIRECTORS

“Darryl Jones”

Darryl Jones
Chief Executive Officer and President

About OTC Markets Group Inc.
OTC Markets Group Inc. operates the OTCQX Best Market, the OTCQB Venture Market, and the Pink Open Market for 10,000 U.S. and global securities. Through OTC Link ATS and OTC Link ECN, the OTC Markets Group connects a diverse network of broker-dealers that provide liquidity and execution services. OTC Markets Group enables investors to easily trade through the broker of their choice and empowers companies to improve the quality of information available for investors.

About the Depository Trust Company
The Depository Trust Company (“DTC”), a subsidiary of the Depository Trust & Clearing Corporation (“DTCC”) and manages the electronic clearing and settlement of publicly traded companies. Securities that are eligible to be electronically cleared and settled through the DTC are considered “DTC eligible.” This reduces costs and accelerates the settlement process for investors and brokers, allowing the stock to be traded over a much wider selection of brokerage firms by coming into compliance with their requirements.

About Isracann Biosciences Inc. (CSE: IPOT) (FRA: A2PT0E) (OTC: ISCNF)
Isracann is an Israeli-based cannabis company focused on becoming a premier cannabis producer offering low-cost production targeting undersupplied, major European marketplaces. Based in Israel’s agricultural sector, Isracann will leverage its development within the most experienced country in the world with respect to cannabis research. The Company has secured agreements within Israel for medicinal marijuana cultivation. For more information visit: www.isracann.com.

The CSE does not accept responsibility for the adequacy or accuracy of this release.
All statements, other than statements of historical fact, included herein are forward-looking statements that involve various risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ, materially from the Company’s expectations are disclosed in the Company’s documents filed from time to time with the Canadian Securities Exchange, the British Columbia Securities Commission, the Ontario Securities Commission, and the Alberta Securities Commission.

Contact
Investor Relations
Toll Free: +1 855.205.0226
Email: inquiries@isracann.com
Web:  www.isracann.com

Primary Logo

Source: GlobeNewswire (November 15, 2019 – 9:00 AM EST)

News by QuoteMedia
www.quotemedia.com

Published at Fri, 15 Nov 2019 14:13:27 +0000

Chemesis International Inc. Reports 2019 Year-End Audited Financial Statements

Chemesis International Inc. Reports 2019 Year-End Audited Financial Statements

Chemesis International Inc. (CSE:CSI) (OTC:CADMF), announces the filing of its audited fiscal 2019 year-end consolidated financial statements and reports on the most recently completed periods.

2019 HIGHLIGHTS

  • The Company reported combined revenues of CAD $7.5M for Q4 and Q3 of fiscal 2019 respectively, with combined gross profit of CAD $1.4M for those two periods.
  • The Company commercialized its California based extraction facility in January 2019 and began to extract THC distillate for finished goods, for sale throughout the state.
  • The Company closed the acquisition of Colombia based, La Finca Interacviva-Arachna Med, a licensed cultivator, producer, distributor, and seller of cannabis products with export abilities into global markets.
  • The Company closed the definitive agreement to acquire an additional extraction and manufacturing facility in Cathedral City, California. The fully licensed facility further allowed the Company to expand its ability to extract THC, CBD and other cannabinoid and terpene products.
  • The Company closed the acquisition of Puerto Rico based, Natural Ventures PR, a licensed medical cultivator, manufacturer and distributor of high-quality cannabis products.

SUBSEQUENT EVENTS

  • The Company announced the closing of CAD $2M in equity financings.
  • Chemesis completed the acquisition of a controlling interest in GSRX Industries Inc. (“GSRX”), a leader in retail cannabis dispensaries, distribution & brand development. Through this acquisition, Chemesis further expands its operations into the retail dispensary markets in California and Puerto Rico. This allows the Company to increase profitability of its existing manufacturing and cultivation products through sales directly to consumers. GSRX’s financial statements will be consolidated under Chemesis International from August 29, 2019 onwards. The consolidated financial statements for the year ended June 30, 2019, do not include GSRX’s operations.
  • Chemesis announced a partnership with Happy Tea and secured a $4M USD purchase order Happy Tea’s CBD product catalogue. The Company will distribute Happy Tea products throughout Puerto Rico and the United States.

Edgar Montero, CEO of Chemesis stated, “the Company’s operations continue to see increases in revenue quarter over quarter and we anticipate our operations will continue to grow as we see significant demand for the products we manufacture and package. The Company’s revenues, accounts receivables and inventory are growing consistently. Chemesis is also putting forth further resources to expand into additional US States to expand the Company’s multi-state operations. The team has created a foundation that we believe will create significant opportunities in 2020.”

Chemesis remains in a stable financial position with access to CAD $32.6M in drawdown equity facilities.

The audited condensed consolidated financial Statements and MD&A for the year ended June 30, 2019 will be filed on SEDAR and available at www.sedar.com.

On Behalf of The Board of Directors
Edgar Montero
CEO and Director

About Chemesis International Inc.

Chemesis International Inc. is a vertically integrated U.S. Multi-State operator with International operations in Puerto Rico and Colombia.

The Company focuses on prudent capital allocation to ensure it maintains a first mover advantage as it enters new markets and is committed to differentiate itself by deploying resources in markets with major opportunities. The Company operates a portfolio of brands that cater to a wide community of cannabis consumers, with focus on quality and consistency.

Chemesis has facilities in both Puerto Rico and California. The Company is positioned to win additional licenses in highly competitive merit-based US states and will expand its footprint to ensure it maintains a first mover advantage.

Investor Relations:

ir@chemesis.com

1 (604) 398-3378

Social Media:

Chemesis.facebook

Chemesis.twitter

Chemesis.instagram

DesertZen.instagram

CaliforniaSap.instagram

Jay&SB.instagram

Forward-Looking Information: This news release contains “forward-looking information” within the meaning of applicable securities laws relating to statements regarding the Company’s business, products and future of the Company’s business, its product offerings and plans for sales and marketing, including finalizing an acquisition in Colombia. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. Readers are cautioned not to place undue reliance on forward-looking information. Such forward-looking statements are subject to risks and uncertainties that may cause actual results, performance and developments to differ materially from those contemplated by these statements depending on, among other things, the risks that the Company’s products and plan will vary from those stated in this news release and the Company may not be able to carry out its business plans as expected. Except as required by law, the Company expressly disclaims any obligation and does not intend to update any forward-looking statements or forward-looking information in this news release. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct and makes no reference to profitability based on sales reported. The statements in this news release are made as of the date of this release.

The CSE has not reviewed, approved or disapproved the content of this press release

SOURCE: Chemesis International Inc.

View source version on accesswire.com:
https://www.accesswire.com/565339/Chemesis-International-Inc-Reports-2019-Year-End-Audited-Financial-Statements

Source: ACCESSWIRE (November 5, 2019 – 9:30 AM EST)

News by QuoteMedia
www.quotemedia.com

Published at Tue, 05 Nov 2019 14:33:15 +0000

Canadian Licensed Producer Canopy Growth to Announce Second Quarter Fiscal 2020 Financial Results

Canadian Licensed Producer Canopy Growth to Announce Second Quarter Fiscal 2020 Financial Results

Canadian Licensed Producer Canopy Growth Corporation (TSX: WEED) (NYSE: CGC) will release its financial results for the second quarter fiscal 2020 ended September 30, 2019 before financial markets open on November 14, 2019.

Logo: Canopy Growth Corporation (CNW Group/Canopy Growth Corporation)

Following the release of its second quarter fiscal 2020 financial results, Canopy Growth will host a conference call and audio webcast with Mark Zekulin, CEO, Mike Lee, EVP & CFO, and Rade Kovacevic, President, at 8:30 AM Eastern Time on November 14, 2019.

Webcast Information
A live audio webcast will be available at:
https://event.on24.com/wcc/r/2118418/9F112F44A037BCC4D081CBECAF10EA1E

Calling Information
Toll Free Dial-In Number: 1-888-231-8191
International Dial-In Number: (647) 427-7450
Conference ID: 3878046

Replay Information
A replay of the call will be accessible by telephone until 11:59 PM ET on February 14, 2020.
Toll Free Dial-in Number: 1-855-859-2056
Replay Password: 3878046

About Canopy Growth Corporation
Canopy Growth (TSX:WEED, NYSE:CGC) is a world-leading diversified cannabis, hemp and cannabis device company, offering distinct brands and curated cannabis varieties in dried, oil and Softgel capsule forms, as well as medical devices through Canopy Growth’s subsidiary, Storz & Bickel GMbH & Co. KG. From product and process innovation to market execution, Canopy Growth is driven by a passion for leadership and a commitment to building a world-class cannabis company one product, site and country at a time. Canopy Growth has operations in over a dozen countries across five continents.

Canopy Growth’s medical division, Spectrum Therapeutics is proudly dedicated to educating healthcare practitioners, conducting robust clinical research, and furthering the public’s understanding of cannabis, and has devoted millions of dollars toward cutting edge, commercializable research and IP development. Spectrum Therapeutics sells a range of full-spectrum products using its colour-coded classification Spectrum system as well as single cannabinoid Dronabinol under the brand Bionorica Ethics.

Canopy Growth operates retail stores across Canada under its award-winning Tweed and Tokyo Smoke banners. Tweed is a globally recognized cannabis brand which has built a large and loyal following by focusing on quality products and meaningful customer relationships.

From our historic public listing on the Toronto Stock Exchange and New York Stock Exchange to our continued international expansion, pride in advancing shareholder value through leadership is engrained in all we do at Canopy Growth. Canopy Growth has established partnerships with leading sector names including cannabis icons Snoop Dogg and Seth Rogen, breeding legends DNA Genetics and Green House Seeds, and Fortune 500 alcohol leader Constellation Brands, to name but a few. Canopy Growth operates eleven licensed cannabis production sites with over 4.7 million square feet of production capacity, including over one million square feet of GMP certified production space. For more information visit www.canopygrowth.com

Cision

View original content to download multimedia:http://www.prnewswire.com/news-releases/canopy-growth-to-announce-second-quarter-fiscal-2020-financial-results-300951970.html

SOURCE Canopy Growth Corporation

View original content to download multimedia: http://www.newswire.ca/en/releases/archive/November2019/05/c2064.html

Media Relations, Caitlin O’Hara, Caitlin.Ohara@canopygrowth.com, 613-291-3239; Vice President, Investor Relations, Tyler Burns, Tyler.Burns@canopygrowth.com, 855-558-9333 ext. 122Copyright CNW Group 2019

Source: Canada Newswire (November 5, 2019 – 11:36 AM EST)

News by QuoteMedia
www.quotemedia.com

Published at Tue, 05 Nov 2019 16:43:05 +0000

CB2 Insights Announces Record Preliminary Unaudited Q3 2019 Revenue of $4.2 Million and Details for Earnings Call

CB2 Insights Announces Record Preliminary Unaudited Q3 2019 Revenue of $4.2 Million and Details for Earnings Call

CB2 Insights (CSE:CBII; OTCQB: CBIIF), a leading data-driven company focused on bringing real-world evidence driven from the point-of-care to the medical cannabis community, announced preliminary unaudited revenue of approximately $4.2 millionfor the three months ended September 30, 2019, representing a 29% growth from the previous quarter. The company also decreased its third quarter adjusted-EBITDA loss by approximately 64% from the previous quarter and saw its first ever month of positive adjusted-EBITDA in the month of August. All figures are reported in Canadian dollars, unless otherwise indicated.

The Company’s achievement in the first nine months of 2019 was, in large part, due to the successful strategic acquisitions of Relaxed Clarity, MedEval Clinics LLC and New Jersey Alternative Medicine (now operating as Canna Care Docs New Jersey). The third quarter of 2019 was the first full reporting period that included the contributions of all three clinical businesses. CB2 now successfully owns and operates one of the largest networks of medical cannabis clinics across the US with a patient registry of 100,000 unique visitors annually. As the team delivers on its efficiency goals and begins to recognize increases in revenue from its technology, data and research services business units, CB2 will look to report full profitability in the coming quarters.

“The continued growth in demand in the market for solutions related to clinically-driven product research has allowed CB2 to start leveraging on our data, technology and CRO capabilities to generate new revenue streams to our already profitable clinical operations in the U.S.,” said Prad Sekar, CEO of CB2 Insights. “We believe we have now arrived at an inflection point in our business and the numbers we are reporting are starting to prove out our multi-dimensional business model. As a team, we will continue to deliver organic growth of our U.S clinical operations, growth in clinical trial and data partnerships, and expand into accretive emerging markets. The Company is now well positioned for continued international growth and ultimately, company-wide profitability.”

CB2 plans to release its results for the three and nine months ended September 30, 2019 on November 8, 2019, with a conference call to discuss its financial results and provide an update on its business operations at 9:00 am Eastern Time.  The call will be hosted by Prad Sekar, CEO of CB2 Insights and Raheel Lalani, VP, Finance of CB2 Insights.

Conference Call Details (phone audio only)

Date: Friday, November 8, 2019
Time: 9:00 a.m. (Eastern Time)
US/Canada Toll Free Dial In: 1-800-319-4610
Toronto Local Dial In: 1-416-915-3239
International Dial In: 1-604-638-5340
Call Name: CB2 Insights Earnings Call

1.The financial information presented in this press release is based on preliminary unaudited financial statements prepared by management, for the third quarter ended September 30, 2019, and is fully qualified by the section in this press release entitled ‘Disclaimer Regarding Financial Information‘.

Financial Measures

This news release makes reference to certain non-IFRS measures, including certain industry metrics. These metrics and measures are not recognized measures under IFRS, do not have meanings prescribed under IFRS and are as a result unlikely to be comparable to similar measures presented by other companies. These measures are provided as information complimentary to those IFRS measures by providing a further understanding of our operating results from the perspective of management. As such, these measures should not be considered in isolation or in lieu of review of our financial information reported under IFRS. This news release uses non-IFRS measures including “EBITDA”, “adjusted EBITDA”.  EBITDA and adjusted EBITDA are commonly used operating measures in the industry but may be calculated differently compared to other companies in the industry. These non-IFRS measures, including the industry measures, are used to provide investors with supplementary measures of our operating performance that may not otherwise be apparent when relying solely on IFRS metrics.

About CB2 Insights

CB2 Insights (CSE:CBII) is a global leader in clinical operations, technology & analytics solutions and research and development services with a mission to mainstream medical cannabis into traditional healthcare.  Providing immediate market access through its wholly-owned clinical network across 12 jurisdictions, proprietary data-driven technology solutions and comprehensive contract research services designed for those in both the medical cannabis and traditional life sciences industries, CB2 Insights is able to support its partners across the entire data and research spectrum.

CB2’s Clinical Operations business unit leverages extensive experience to develop clinical models with standard operating procedures, advanced workflows, training and ongoing management support.  CB2 also owns and operates its own speciality clinics including the brands Canna Care Docs and Relaxed Clarity which assess nearly 100,000 patients seeking medical cannabis treatment to provide immediate market access to US-based product manufacturers for clinical trial and research programs.

The Company has built both electronic data capture (EDC) and clinical data management software (CDMS) which work to support its partners of any size to execute their data and clinical strategies.

CB2 also offers comprehensive contract research organization (CRO) services including full scale clinical trial management, trial design, monitoring and other key research functions used by licensed producers, multi-state operators and traditional pharmaceutical companies entering the medical cannabis space.

For more information please visit www.cb2insights.com.

For additional information, please contact:

Kim Nguyen – Director, Investor Relations
1.855.847.4999  ext. 212
kim.nguyen@cb2insights.com

Disclaimer Regarding Financial Information

The financial information presented in this press release is based on preliminary, unaudited financial statements prepared by management, for the third quarter ended September 30, 2019. Accordingly, such financial information may be subject to change. All information contained in this press release will be qualified with reference to the interim/ unaudited financial results for the three and nine month period ending September 30, 2019, which will be released on November 8, 2019, and will be posted on sedar.com. While the Company does not expect there to be any material changes to the financial information provided in the press release, any variation between the Company’s actual results and the preliminary financial information set forth herein may be material.

Forward Looking Statements

Statements in this news release that are forward-looking statements are subject to various risks and uncertainties concerning the specific factors disclosed here and elsewhere in CB2’s filings with Canadian securities regulators. When used in this news release, words such as “will, could, plan, estimate, expect, intend, may, potential, believe, should,” and similar expressions, are forward-looking statements.

Forward-looking statements may include, without limitation, statements regarding the opportunity to provide services and software to the U.S. cannabis industry.

Although CB2 has attempted to identify important factors that could cause actual results, performance or achievements to differ materially from those contained in the forward-looking statements, there can be other factors that cause results, performance or achievements not to be as anticipated, estimated or intended, including, but not limited to: dependence on obtaining regulatory approvals; investing in target companies or projects which have limited or no operating history and are subject to inconsistent legislation and regulation; change in laws; reliance on management; requirements for additional financing; competition; hindering market growth and state adoption due to inconsistent public opinion and perception of the medical-use and recreational-use marijuana industry; and regulatory or political change.

There can be no assurance that such information will prove to be accurate or that management’s expectations or estimates of future developments, circumstances or results will materialize. As a result of these risks and uncertainties, the results or events predicted in these forward-looking statements may differ materially from actual results or events.

Accordingly, readers should not place undue reliance on forward-looking statements. The forward-looking statements in this news release are made as of the date of this release. CB2 disclaims any intention or obligation to update or revise such information, except as required by applicable law, and CB2 does not assume any liability for disclosure relating to any other company mentioned herein. 

No securities regulator or exchange has reviewed, approved, disapproved, or accepts responsibility for the content of this news release.

Primary Logo

Published at Fri, 01 Nov 2019 12:16:35 +0000

Planet 13 Production Facility Begins Operations

Planet 13 Production Facility Begins Operations

Planet 13 Holdings Inc. (CSE: PLTH) (OTCQX: PLNHF), a leading vertically-integrated Nevada based cannabis company, announced today that it has been granted final permits to begin production at its 15,000 square foot customer-facing production facility co-located at the Planet 13 Cannabis Entertainment Complex.

Planet 13 Production Facility Begins Operations (CNW Group/Planet 13 Holdings Inc.)

“Since we opened the SuperStore and began serving approximately 2,000 customers per day, we haven’t been able to keep our inhouse brands in stock. Our new production facility will increase our production capacity by over ten times and help us to meet the demand. Currently, about 15% of SuperStore sales are Planet 13’s in-house brands, we expect with the increase in production capacity to be able to capture a much larger share of SuperStore sales and expand into the wholesale market,” said Bob Groesbeck, Co-CEO of Planet 13.

The Production Facility offers an immersive experience to customers, featuring 115 feet of windows where visitors can watch and learn what goes into the creation of individual products.  Interactive kiosks are available near the production viewing area to teach customers what goes into making their favourite product, offering Planet 13 a powerful branding opportunity.

The highly automated Production Facility utilizes robotics to lower costs and is capable of processing 600 lbs of plant biomass per day at full production, a throughput increase of approximately 1,300% from Planet 13’s current production facility. The expansion allows Planet 13 to increase the production of its existing TRENDI and Leaf & Vine vape and concentrate lines and begin production of its two new edible lines, HaHa Gummies and Dreamland Chocolates along with its beverage line, Elysium.

About Planet 13
Planet 13 (www.planet13holdings.com) is a vertically integrated cannabis company based in Nevada, with award-winning cultivation, production and dispensary operations in Las Vegas – the entertainment capital of the world. Planet 13’s mission is to build a recognizable global brand known for world-class dispensary operations and a creator of innovative cannabis products. Planet 13’s shares trade on the Canadian Stock Exchange (CSE) under the symbol PLTH and OTCQX under the symbol PLNHF.

Cautionary Note Regarding Forward-Looking Information

This news release contains “forward-looking information” and “forward-looking statements” (collectively, “forward-looking statements”) within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as “expects”, or “does not expect”, “is expected”, “anticipates” or “does not anticipate”, “plans”, “budget”, “scheduled”, “forecasts”, “estimates”, “believes” or “intends” or variations of such words and phrases or stating that certain actions, events or results “may” or “could”, “would”, “might” or “will” be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. In this news release, forward looking-statements relate to, among other things, future expansion plans.

These forward-looking statements are based on reasonable assumptions and estimates of management of the Company at the time such statements were made. Actual future results may differ materially as forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to materially differ from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors, among other things, include: final regulatory and other approvals or consents; fluctuations in general macroeconomic conditions; fluctuations in securities markets; expectations regarding the size of the Nevada cannabis market and changing consumer habits; the ability of the Company to successfully achieve its business objectives; plans for expansion; political and social uncertainties; inability to obtain adequate insurance to cover risks and hazards; and the presence of laws and regulations that may impose restrictions on cultivation, production, distribution and sale of cannabis and cannabis related products in the State of Nevada; and employee relations. Although the forward-looking statements contained in this news release are based upon what management of the Company believes, or believed at the time, to be reasonable assumptions, the Company cannot assure shareholders that actual results will be consistent with such forward-looking statements, as there may be other factors that cause results not to be as anticipated, estimated or intended. Readers should not place undue reliance on the forward-looking statements and information contained in this news release. The Company assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law.

The Company is indirectly involved in the manufacture, possession, use, sale and distribution of cannabis in the recreational and medicinal cannabis marketplace in the United States through its subsidiary MMDC. Local state laws where MMDC operates permit such activities however, these activities are currently illegal under United States federal law. Additional information regarding this and other risks and uncertainties relating to the Company’s business are contained under the heading “Risk Factors” in the Company’s annual information form dated April 30, 2019 filed on its issuer profile on SEDAR at www.sedar.com.

No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein.

SOURCE Planet 13 Holdings Inc.

View original content to download multimedia: http://www.newswire.ca/en/releases/archive/November2019/01/c0342.html

LodeRock Advisors Inc., Planet 13 Investor Relations, mark.kuindersma@loderockadvisors.com (416) 519-2156 ext. 2230; Robert Groesbeck or Larry Scheffler, Co-Chief Executive Officers, ir@planet13lasvegas.comCopyright CNW Group 2019

Published at Fri, 01 Nov 2019 12:24:41 +0000

Namaste Technologies Announces Changes to Management and Board of Directors

Namaste Technologies Announces Changes to Management and Board of Directors

Namaste Technologies Inc. (TSXV: N) (FRANKFURT: M5BQ) (OTCMKTS: NXTTF), a leading online platform for cannabis products, accessories, and responsible education, is pleased to announce the appointment of Mr. Baran Dilaver to its board of directors and Ms. Annie Holmes as chief financial officer. Ms. Holmes succeeds Ken Ngo who will be leaving Namaste to pursue another opportunity.

“I would like to welcome both Mr. Dilaver and Ms. Holmes to the Namaste team as they bring extensive experience and capabilities as we move the Company into the next stage of growth,” said Meni Morim, CEO of Namaste Technologies. “The addition of Baran and Annie, two outstanding individuals with significant experience in cannabis, consumer packaged goods and financial strategies, will help drive the Company forward.”

Mr. Baran Dilaver is an entrepreneur, creator, and accomplished executive. He has served as CEO and COO at public and private companies, launched over a dozen well-known brands worldwide, and has developed many award-winning products for prominent institutions. His previous venture, Firefly Vapor, where he served as the COO and CMO, was recently sold to a larger company and the ensuing company went public in early 2019. Baran recently helped facilitate one of the largest Series A capital raises in cannabis, $35M for Mile High Labs, and co-founded FutureScape, a technology focused product design and branding firm, and AccessX, a boutique venture capital firm, focused on biotech and cannabis. Mr. Dilaver has an extensive background in cannabis and consumer packaged goods and is a frequent speaker at industry conferences. He studied Economics at the University of California, Berkeley, where he excelled in academics and athletics earning scholarships in both fields.

Ms. Annie Holmes is a strategic thinker with over 15 years of senior executive experience leading corporations through complex restructurings, international expansion and large capital transactions. As Principal of Chartered Course, she provided strategic and financial advice to public and private clients in both the domestic and international markets. She has held the position of chief financial officer for a number of private companies and senior financial roles with publicly traded Smart Employee Benefits Inc. and Katanga Mining Inc. Ms. Holmes received her ICD.D designation from the Rotman School of Management, holds a Bachelor of Arts Honours from the University of Toronto, and earned her Chartered Accountant designation with Grant Thornton.

In accordance with the terms of the consulting agreement between Namaste and Ms. Holmes providing for the provision of services as chief financial officer of the Company, Ms. Holmes is entitled to participate in the Company’s stock option plan. Subject to approval by the board of directors of the Company, Ms. Holmes will be granted stock options in connection with the commencement of her engagement. A subsequent news release disclosing the number of stock options to be granted to Ms. Holmes and the terms of such stock options will be disseminated upon approval by the board of directors.

Namaste also announces that Kenneth Jones has resigned from the Company’s board of directors. The Company would like to thank Mr. Jones and Mr. Ngo for their service and dedication and wish them well in their future endeavors.

About Namaste Technologies Inc.
With headquarters in Toronto, ON, and offices in both B.C. and around the globe, Namaste Technologies is the world’s leading online platform for cannabis products, accessories, and responsible education. The company’s ‘everything cannabis store’, CannMart.com, provides customers with a diverse selection of hand-picked products from a multitude of federally-licensed cultivators, all on one convenient site. Namaste’s global technology and continuous innovation address local needs in a burgeoning cannabis industry requiring smart solutions. For further information about Namaste, please visit NamasteTechnologies.com

Information on the Company and its many products can be accessed through the links below:

NamasteTechnologies.com
NamasteMD.com
Cannmart.com
NamasteVapes.ca
Everyonedoesit.ca

FORWARD-LOOKING INFORMATION – This news release contains “forward-looking information” within the meaning of applicable securities laws. All statements contained herein that are not historical in nature contain forward-looking information. Forward-looking information can be identified by words or phrases such as “may”, “expect”, “likely”, “should”, “would”, “plan”, “anticipate”, “intend”, “potential”, “proposed”, “estimate”, “believe” or the negative of these terms, or other similar words, expressions and grammatical variations thereof, or statements that certain events or conditions “may” or “will” happen. The forward-looking information contained herein is made as of the date of this press release and is based on assumptions management believed to be reasonable at the time such statements were made, including management’s perceptions of Namaste’s standing in the online marketplace for cannabis products, future growth, the proposed grant of incentive stock options to Annie Holmes in connection with her engagement as chief financial officer of the Company, results of operations, operational matters, historical trends, current conditions and expected future developments, as well as other considerations that are believed to be appropriate in the circumstances. While we consider these assumptions to be reasonable based on information currently available to management, there is no assurance that such expectations will prove to be correct. By their nature, forward-looking information is subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct and that objectives, strategic goals and priorities will not be achieved. A variety of factors, including known and unknown risks, many of which are beyond our control, could cause actual results to differ materially from the forward-looking information in this press release. Such factors include, without limitation: risks relating to the Company’s ability to execute its business strategy and the benefits realizable therefrom, risks specifically related to the Company’s international operations, and risks relating to the market price of the Common Shares. Additional risk factors can also be found in the Company’s current MD&A and annual information form, both of which have been filed under the Company’s SEDAR profile at www.sedar.com. Readers are cautioned not to put undue reliance on forward-looking information. The Company undertakes no obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable law. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release or has in any way approved or disapproved of the contents of this press release.

Cision

View original content to download multimedia:http://www.prnewswire.com/news-releases/namaste-technologies-announces-changes-to-management-and-board-of-directors-300949835.html

SOURCE Namaste Technologies Inc.

View original content to download multimedia: http://www.newswire.ca/en/releases/archive/November2019/01/c1243.html

Incite Capital Markets, Eric Negraeff / Darren Seed, Ph: 604.493.2004; For Meni Morim, CEO, Email: ir@namastetechnologies.comCopyright CNW Group 2019

Published at Fri, 01 Nov 2019 12:33:36 +0000

Vapen MJ Announces Cannabis THC Extraction, Production and Cultivation Partnership in Oklahoma

Vapen MJ Announces Cannabis THC Extraction, Production and Cultivation Partnership in Oklahoma

Vapen MJ (OTCQX:VAPNF; CSE: VAPN) (“Vapen MJ”) a fully integrated manufacturer and distributor of cannabis THC and hemp CBD products under the Vapen Brand, leveraging core expertise in extraction, outdoor cultivation and marketing to build wholesale distribution through revenue and profit sharing partnerships, announced today a cannabis THC production, extraction and cultivation partnership with the principals and founders of Texoma House of Cannabis to form Vapen Oklahoma, LLC in Oklahoma .

Texoma House of Cannabis has a licensed retail dispensary, as well as Texoma Cultivation greenhouse and outdoor growing operations in Madill, OK. Oklahoma is one of the fastest growing medical marijuana markets in the U.S. according to the August 2019 Annual Marijuana Business Factbook report, based on the average number of patients as a percentage of the population.

The new, state-of-the-art extraction and production facility is anticipated to be fully operational and selling product wholesale to licensed Oklahoma dispensaries throughout the state by the end of 2019. Vapen MJ will provide the Vapen brand, standard operating procedures (SOPs), and back office support for the partnership. The partnership with Texoma will facilitate the launch of Vapen branded product including a line of THC concentrates, edibles and extraction products to dispensaries in the state of Oklahoma .

“We are strategically adding capacity in a new market that has one of the fastest-growing medical marijuana patient populations. We will be launching Vapen branded, safe products that deliver our high quality and purity standards,” commented Thai Nguyen , Founder and Chief Executive Officer of Vapen MJ. “Our partner, with a retail presence and outdoor growing capability in the state of Oklahoma as well as greenhouse operations, has built a solid reputation for quality cannabis products. This relationship underscores our commitment to expanding through partnerships in new markets as we execute our growth strategy to expand our U.S. presence and increase our brand awareness.”

For more information please visit our websites at www.vapenmj.com or www.vapencbd.com.

About Texoma House of Cannabis

Texoma House of Cannabis is a state-licensed marijuana dispensary in Southern Oklahoma that stemmed from a desire to supply top-quality hemp-derived alternative medicine to the people who need it in the Sooner State. We aim to become the go-to resource for anything related to medical marijuana — from serving as an educational resource on the latest rules and regulations and how to apply for a medical marijuana patient license to helping customers determine and purchase the best products and accessories to manage their symptom relief. THC Texoma is a proud member of the National Cannabis Industry Association.  www.THCtexoma.com

About Vapen MJ Ventures

Vapen MJ, through its wholly-owned subsidiaries, currently operates in the US as an agricultural technology, services and property management company utilizing a full vertical integration business model to oversee and execute all aspects of cultivation, extraction, manufacturing (THC and CBD cartridges, concentrates, edibles), retail dispensary, and wholesale distribution of high margin Cannabis THC and Hemp CBD products under the Vapen Brand.  Vapen MJ expansion plans include partnering with cannabis license holders and hemp farms in multiple states within the US.

We seek Safe Harbour.

Cision
Cision

View original content:http://www.prnewswire.com/news-releases/vapen-mj-announces-cannabis-thc-extraction-production-and-cultivation-partnership-in-oklahoma-300946725.html

SOURCE Vapen MJ Ventures Corporation

Share

Share - Facebook


Share - Twitter

Authored By

Anthony Varrell

Anthony Varrell is Managing Director of StoneBridge Partners LLC. SBP continues to drive market awareness for leading firms in the cannabis industry throughout the U.S. and abroad.

Published at Tue, 29 Oct 2019 13:13:45 +0000

Canopy Growth Launches 27th Retail Banner Location: Welcome Tokyo Smoke – Brandon, Manitoba

Canopy Growth Launches 27th Retail Banner Location: Welcome Tokyo Smoke – Brandon, Manitoba

Canopy Growth Corporation (TSX: WEED) (NYSE: CGC) is pleased to launch its 27th retail location and introduce customers in Brandon, Manitoba to its second location, conveniently located in Brandon’s Corral Centre.

Canopy Growth Launches 27th Retail Banner Location: Welcome Tokyo Smoke - Brandon, Manitoba (CNW Group/Canopy Growth Corporation)

“Retail presence is a key driver of brand recognition in a competitive market,” said Rade Kovacevic, President, Canopy Growth. “With twenty-seven locations already open and many more in the works we are confident we’re establishing a national presence that can pay dividends for years to come.”

The province of Manitoba has effectively rolled out their retail strategy and has ensured that the brands Canadians know and trust are easily accessible within each community. As we have seen, having physical retail locations has proven to be the most effective way to build brand loyalty by creating reliable educational hubs, supplied with high-quality, regulated products.

Tokyo Smoke, Canada’s award-winning and design-focused cannabis retailer is now present across two provinces, while Canopy’s second retail banner, Tweed, is located across four provinces. With 27 retail stores either owned or licensed, Canopy’s retail banners represent the 4thlargest cannabis retail network in Canada.

The Tokyo Smoke store team looks forward to meeting its neighbours and creating a hub for adult recreational cannabis education and culture. The company is committed to building on its retail presence to drive brand awareness and continue to offer consumers convenient access to quality cannabis products, while combatting the black market through an effective retail structure.

Here’s to Future (retail) Growth.

About Canopy Growth Corporation
Canopy Growth (TSX:WEED, NYSE:CGC) is a world-leading diversified cannabis, hemp and cannabis device company, offering distinct brands and curated cannabis varieties in dried, oil and Softgel capsule forms, as well as medical devices through Canopy Growth’s subsidiary, Storz & Bickel GMbH & Co. KG. From product and process innovation to market execution, Canopy Growth is driven by a passion for leadership and a commitment to building a world-class cannabis company one product, site and country at a time. Canopy Growth has operations in over a dozen countries across five continents.

Canopy Growth’s medical division, Spectrum Therapeutics is proudly dedicated to educating healthcare practitioners, conducting robust clinical research, and furthering the public’s understanding of cannabis, and has devoted millions of dollars toward cutting edge, commercializable research and IP development. Spectrum Therapeutics sells a range of full-spectrum products using its colour-coded classification Spectrum system as well as single cannabinoid Dronabinol under the brand Bionorica Ethics.

Canopy Growth operates retail stores across Canada under its award-winning Tweed and Tokyo Smoke banners. Tweed is a globally recognized cannabis brand which has built a large and loyal following by focusing on quality products and meaningful customer relationships.

From our historic public listing on the Toronto Stock Exchange and New York Stock Exchange to our continued international expansion, pride in advancing shareholder value through leadership is engrained in all we do at Canopy Growth. Canopy Growth has established partnerships with leading sector names including cannabis icons Snoop Dogg and Seth Rogen, breeding legends DNA Genetics and Green House Seeds, and Fortune 500 alcohol leader Constellation Brands, to name but a few. Canopy Growth operates eleven licensed cannabis production sites with over 10.5 million square feet of production capacity, including over one million square feet of GMP certified production space. For more information visit www.canopygrowth.com

Notice Regarding Forward Looking Statements
This news release contains “forward-looking statements” within the meaning of the United States Private Securities Litigation Reform Act of 1995 and “forward-looking information” within the meaning of applicable Canadian securities legislation. Often, but not always, forward-looking statements and information can be identified by the use of words such as “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Forward-looking statements or information involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Canopy Growth or its subsidiaries to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements or information contained in this news release. Examples of such statements include statements with respect to future product format offerings. Risks, uncertainties and other factors involved with forward-looking information could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information, including the Company’s ability to satisfy provincial sales contracts or provinces purchasing all cannabis allocated to them, and such risks contained in the Company’s annual information form dated June 25, 2019 and filed with Canadian securities regulators available on the Company’s issuer profile on SEDAR at www.sedar.com. Although the Company believes that the assumptions and factors used in preparing the forward-looking information or forward-looking statements in this news release are reasonable, undue reliance should not be placed on such information and no assurance can be given that such events will occur in the disclosed time frames or at all. The forward-looking information and forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking information or forward-looking information to reflect new information, subsequent events or otherwise unless required by applicable securities laws.

Cision

View original content to download multimedia:http://www.prnewswire.com/news-releases/canopy-growth-launches-27th-retail-banner-location-welcome-tokyo-smoke—brandon-manitoba-300941170.html

SOURCE Canopy Growth Corporation

Published at Fri, 18 Oct 2019 12:30:08 +0000

Vapen MJ President and CFO Bob Brilon to Present at Upcoming Investor Conferences

Vapen MJ President and CFO Bob Brilon to Present at Upcoming Investor Conferences

Vapen MJ (OTCQX:VAPNF; CSE:VAPN) (“Vapen MJ”) a fully integrated manufacturer and distributor of cannabis THC and hemp CBD products under the Vapen Brand, leveraging core expertise in extraction and marketing to build wholesale distribution through revenue and profit sharing partnerships, announced today that Bob Brilon, President and CFO will be presenting at the following conferences in October.

The Microcap Rodeo

  • Presentation date and time: Tuesday, October 15 at 3:50 pm CT with management hosting one-on-one meetings the same day
  • Location: Hilton Austin, Austin, TX
  • For more information visit the conference website: https://microcaprodeo.com

Benzinga Cannabis Capital Conference

  • Presentation date and time: Wednesday, October 23 at 2:20pm CT with management hosting one-on-one meetings the same day
  • Location: Palmer House, Chicago, IL
  • For more information visit the conference website and use code VAPENVIP for 20% off admission: https://benzingacannabisconference.com/chicago/

For more information on Vapen MJ, please visit our websites at www.VapenMJ.com or www.VapenCBD.com.

About Vapen MJ Ventures

Vapen MJ, through its wholly-owned subsidiaries, currently operates in the US as an agricultural technology, services and property management company utilizing a full vertical integration business model to oversee and execute all aspects of cultivation, extraction, manufacturing (THC and CBD cartridges, concentrates, edibles), retail dispensary, and wholesale distribution of high margin Cannabis THC and Hemp CBD products under the Vapen Brand. Vapen MJ expansion includes partnering with cannabis license holders and hemp farms in multiple states within the US.

Forward Looking Statements
We Seek Safe Harbour.

Cision

View original content:http://www.prnewswire.com/news-releases/bob-brilon-vapen-mj-president-and-cfo-to-present-at-upcoming-investor-conferences-300936920.htmlSOURCE Vapen MJ Ventures Corporation

Copyright (c) 2019 PR Newswire Association,LLC. All Rights Reserved.

Published at Fri, 11 Oct 2019 13:05:23 +0000

Aleafia Health Completes Construction, Secures Full Occupancy at Paris Processing Facility Expansion

Aleafia Health Completes Construction, Secures Full Occupancy at Paris Processing Facility Expansion

Aleafia Health Inc. (TSX: ALEF, OTC: ALEAF, FRA: ARAH) (“Aleafia Health” or the “Company”) has completed the construction of its Paris Processing facility’s Phase II expansion and secured full site occupancy on October 4, 2019, following the successful completion of County of Brant inspections. The Paris Phase II expansion is a 30,000 sq. ft. facility entirely dedicated to the extraction, production, packaging and distribution of high-margin, value-added cannabis health and wellness products.

The expansion builds upon the current, licensed and operational Paris facility, which features cultivation rooms and handles all extraction, packaging and order fulfillment for Aleafia Health’s medical, adult-use and international sales.

Paris will feature an initial 115,000 kg dried flower equivalent (“DFE”) extraction capacity, a 2,775 per cent increase over the Company’s current 4,000 kg DFE extraction capacity. The Company expects that Paris can through-put all dried flower grown by Aleafia Health, including at its newly expanded, 86-acre Port Perry Outdoor Grow site.

To complete the final stage of securing its required Licence Amendment, the Company’s wholly-owned subsidiary, Emblem Cannabis Corp., expects to submit its final evidence package to Health Canada this October, demonstrating the facility’s operational readiness.

PURPOSE-BUILT TO EU-GMP STANDARDS FOR EXPORT TO EU MARKET

The facility is purpose-built to meet European Union Good Manufacturing Practices (“EU-GMP”) certification requirements. EU-GMP certified facilities demonstrate the highest level of pharmaceutical-grade quality, and securing the certification will allow Aleafia Health to begin exporting finished goods including cannabis oils and capsules to the EU.

Through the Aleafia Health Germany joint-venture with German pharmaceutical wholesaler and logistics company Acnos Pharma GmbH, Aleafia will gain access to the burgeoning German medical cannabis market, with access to 22,000 pharmacies and 110 distribution centres.

115,000 KG EXTRACTION CAPACITY WITH ABILITY FOR FURTHER EXPANSION

The Paris expansion will rapidly accelerate Aleafia Health’s production capacity, and ability to create a wide variety of differentiated products across multiple categories. It has been built specifically to allow for further, significant expansions of extraction capacity by utilizing additional machinery. For instance, the existing capital expenditures budget accounts for additional ethanol extraction machinery that would bring total capacity to 190,000 kg DFE and would take approximately eight weeks to bring online.

Each element of the extraction and production process occupies a purpose-built, dedicated room in the facility, maximizing through-put ability and operational efficiency. Highlights include:

  • 40,000 kg DFE of supercritical C02 extraction which is primarily used for the production of pharmaceutical-grade oil-based products including capsules and sprays
  • 75,000 kg DFE of ethanol extraction, which produces a tasteless distillate ideally suited for new product formats including edibles, beverages and extracts
  • In-house analytical testing and quality assurance equipment, allowing for products to reach market two to three weeks earlier than with the use of external third-party testing
  • Production and packaging machinery along with space dedicated to creating new, differentiated product formats soon available in the Canadian market
  • A dedicated laboratory for ongoing R&D, product development and continued process optimization
  • A logistics centre handling order fulfilment to medical patients, provincial wholesalers and all international exports
  • The entire expansion project, including machinery for yet to be announced new product formats, falls within the Company’s fully funded, previously reported capital expenditures budget

“The Paris expansion represents the crown jewel of Aleafia Health’s cannabis ecosystem. This facility will allow us to rapidly expand the production of high-margin derivative products, while adding new, differentiated formats that are grown, processed, packaged and exported by Aleafia Health,” said CEO Geoffrey Benic. “We look forward to bringing the next generation of cannabis products to market, while greatly expanding our international footprint in Germany, Australia and beyond.”

For Investor and Media Relations, please contact:

Nicholas Bergamini, VP Investor Relations
1-833-TSX-ALEF (879-2533)
IR@AleafiaHealth.com
LEARN MORE: www.AleafiaHealth.com

About Aleafia Health:

Aleafia Health is a leading, vertically integrated cannabis health and wellness company with four primary business units: Cannabis Cultivation & Products, Health & Wellness Clinics, Cannabis Education, and Consumer Experience with ecommerce, retail distribution and provincial supply agreements.

Aleafia Health owns three major cannabis product & cultivation facilities, two of which are licensed and operational including the first large-scale, operational outdoor cultivation facility in Canadian history. The Company produces a diverse portfolio of commercially proven, high-margin derivative products including oils, capsules and sprays. Aleafia Health operates the largest national network of medical cannabis clinics and education centres staffed by MDs, nurse practitioners and educators and has international operations in three continents.

Innovation is at the heart of Aleafia Health competitive advantage. The Company maintains a medical cannabis dataset with over 10 million data points to inform proprietary illness-specific product development and its highly differentiated education platform FoliEdge Academy. The Company is committed to creating sustainable shareholder value and has been named the 2019 top performing company of the year by the TSX Venture Exchange prior to graduation to the TSX.

Forward Looking Information

This news release contains forward-looking information within the meaning of applicable Canadian and United States securities laws. Often, but not always, forward-looking information can be identified by the use of words such as “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes” or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Forward-looking information involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company or its subsidiaries to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained in this news release. Risks, uncertainties and other factors involved with forward-looking information could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information, including risks contained in the Company’s annual information form filed with Canadian securities regulators available on the Company’s SEDAR profile at www.sedar.com. Although the Company believes that the assumptions and factors used in preparing the forward-looking information in this news release are reasonable, undue reliance should not be placed on such information and no assurance can be given that such events will occur in the disclosed time frames or at all. The forward-looking information included in this news release are made as of the date of this news release and the Company does not undertake any obligation to publicly update such forward-looking information to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

Primary Logo

Published at Mon, 07 Oct 2019 11:03:09 +0000